BIOMAT Database Logo BIOMAT Database Logo

Treatment of skeletal disease in breast cancer: a controlled clodronate trial. 1987

I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Department of Radiotherapy, University of Helsinki, Finland.

Normocalcaemic breast cancer patients with progressive osteolytic bone metastases were treated with clodronate 1.6 g/day (17) or placebo (17) for 12 months. Bone pain, extension of bone metastases and formation of new osteolytic foci were reduced by clodronate, and development of severe hypercalcaemia was prevented. After withdrawal of treatment the patients were followed-up for at at least 12 months. New bone metastases developed in both groups. There were, however, less fractures and less hypercalcaemia in the clodronate than in the placebo group. The survival rate was higher in the clodronate group than in the placebo group. No haematological toxicity was observed in the clodronate group.

UI MeSH Term Description Entries
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004002 Clodronic Acid A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. Clodronate,Dichloromethylene Diphosphonate,Bonefos,Cl2MDP,Clodronate Disodium,Clodronate Sodium,Dichloromethane Diphosphonate,Dichloromethanediphosphonate,Dichloromethanediphosphonic Acid,Dichloromethylene Biphosphonate,Dichloromethylenebisphosphonate,Acid, Clodronic,Acid, Dichloromethanediphosphonic,Biphosphonate, Dichloromethylene,Diphosphonate, Dichloromethane,Diphosphonate, Dichloromethylene,Disodium, Clodronate,Sodium, Clodronate
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Treatment of skeletal disease in breast cancer with clodronate.
January 1991, Bone,
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
August 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients.
January 2004, Acta oncologica (Stockholm, Sweden),
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
January 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Clodronate decreases the frequency of skeletal metastases in women with breast cancer.
December 1996, Bone,
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Re: A randomized controlled trial of Intravenous clodronate.
May 1998, Journal of pain and symptom management,
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Clodronate in metastatic breast cancer.
December 1998, The New England journal of medicine,
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Clodronate in metastatic breast cancer.
December 1998, The New England journal of medicine,
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Clodronate in metastatic breast cancer.
December 1998, The New England journal of medicine,
I Elomaa, and C Blomqvist, and L Porkka, and C Lamberg-Allardt, and G H Borgström
Adjuvant clodronate in breast cancer.
January 2005, Acta oncologica (Stockholm, Sweden),
Copied contents to your clipboard!